Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shield TherapeuticsFRA:1JS EV-to-EBITDA is -12.64 as of Jul. 15, 2026. The stock has 5 warning signs investors should review. Among 740 Drug Manufacturers companies, Shield Therapeutics ranks worse than 135135% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shield Therapeutics's enterprise value is €93.75 Mil.
Shield Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.42 Mil. Therefore, Shield Therapeutics's EV-to-EBITDA for today is -12.64.
The historical rank and industry rank for Shield Therapeutics's EV-to-EBITDA or its related term are showing as below:
FRA:1JS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -88.21 Med: -2.05 Max: 86.13
Current: -12.67
During the past 12 years, the highest EV-to-EBITDA of Shield Therapeutics was 86.13. The lowest was -88.21. And the median was -2.05.
FRA:1JS's EV-to-EBITDA is ranked worse than 100% of 740
companies
in the Drug Manufacturers industry
Industry Median: 13.025
vs FRA:1JS: -12.67
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shield Therapeutics's PE Ratio (TTM) for today is calculated as:
Shield Therapeutics's share price for today is €0.068.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shield Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.018.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Shield Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1JS vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's EV-to-EBITDA falls into.
Shield Therapeutics's current Enterprise Value is €93.75 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shield Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shield Therapeutics (FRA:1JS) has a EV-to-EBITDA of -12.64 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shield Therapeutics. According to the industry distribution chart, Shield Therapeutics ranks #999999 out of 740 companies in the Drug Manufacturers industry.
Is Shield Therapeutics' EV-to-EBITDA too high?
Shield Therapeutics' current EV-to-EBITDA is -12.64. Based on the distribution chart, Shield Therapeutics ranks #999999 out of 740 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Shield Therapeutics' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #999999 out of 740 companies for EV-to-EBITDA. This places Shield Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 740 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shield Therapeutics. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current EV-to-EBITDA is -12.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (FRA:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current EV-to-EBITDA is -12.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shield Therapeutics (FRA:1JS), the current EV-to-EBITDA is -12.64 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1JS has been successfully added to your 
